Search

everythinglearnresearchcommunity

for

Search:↓

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Menopause reduces skin collagen and elasticity, and while estrogen therapy can help, its risks require careful consideration.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.

Melasma is a skin condition linked to female hormones, genetics, UV exposure, and certain medications, but not to pituitary, adrenal, or thyroid diseases.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

The conclusion is that proper evaluation and treatment of hair loss in midlife women is important, considering the emotional impact and potential for various treatments.

Hormones affect skin aging, and treatments targeting hormonal balance may improve skin health.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

Neuroactive steroids could become safe, effective treatments with more understanding of their complex brain actions and metabolism.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Hair loss in Androgenetic alopecia (AGA) is due to altered cell sensitivity to hormones, not increased hormone levels. Hair growth periods shorten over time, causing hair to become thinner and shorter. This is linked to miscommunication between cell pathways in hair follicles. There's also a change in gene expression related to blood vessels and cell growth in balding hair follicles. The exact molecular causes of AGA are still unclear.

Menopause causes dry skin, wrinkles, and hair changes, with hormone therapy helping but not recommended just for these issues.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Using anabolic androgenic steroids can cause serious, lasting health problems in many parts of the body.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

Eating a balanced diet with specific nutrients can help manage menopause symptoms and prevent related health issues.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.